Suzhou Ribo Life Science’s RBD2080 siRNA Drug Receives Australian Clinical Trial Approval
China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...
Drug
CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...
Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US
Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...
Xellsmart’s iPSC Therapy XS-228 Receives FDA Approval for ALS Study
Suzhou-based stem-cell startup Xellsmart announced that the U.S. FDA has approved its regulatory study of...
Huadong Medicine’s HDM1005 Receives NMPA Approval for OSA Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its HDM1005, a long-acting GLP-1/GIP receptor...
Pfizer’s Hympavzi (Marstacimab) Launched in China’s Boao Lecheng Pilot Zone for Hemophilia
Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s...
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...
CanSino Biologics Receives NMPA Approval for DTcP Hib MCV4 Combined Vaccine
China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular...
Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment
Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...
QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...
Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved...
Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China
Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...
Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand
Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...
CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the start of a Phase III clinical...
Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment
Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...
Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials
China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...
Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...
Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a...
Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S....
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...